
Andreas D Meid

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8874227/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity. Journal of Stroke, 2022, 24, 88-97.	1.4	8
2	Machine learning for tumor growth inhibition: Interpretable predictive models for transparency and reproducibility. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 257-261.	1.3	3
3	Predicting Hospital Readmissions from Health Insurance Claims Data: A Modeling Study Targeting Potentially Inappropriate Prescribing. Methods of Information in Medicine, 2022, 61, 055-060.	0.7	1
4	Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy. European Journal of Clinical Pharmacology, 2022, 78, 1127-1136.	0.8	2
5	A prognostic model predicted deterioration in health-related quality of life in older patients with multimorbidity and polypharmacy. Journal of Clinical Epidemiology, 2021, 130, 1-12.	2.4	7
6	Comparison of Five Lists to Identify Potentially Inappropriate Use of Non-Steroidal Anti-Inflammatory Drugs in Older Adults. Pain Medicine, 2021, 22, 1962-1969.	0.9	4
7	Predicting negative health outcomes in older general practice patients with chronic illness: Rationale and development of the PROPERmed harmonized individual participant data database. Mechanisms of Ageing and Development, 2021, 194, 111436.	2.2	3
8	Disease-dependent variations in the timing and causes of readmissions in Germany: A claims data analysis for six different conditions. PLoS ONE, 2021, 16, e0250298.	1.1	8
9	Renal Safety of Hydroxyethyl starch 130/0.42 After Cardiac Surgery: A Retrospective Cohort Analysis. Drug Safety, 2021, 44, 1311-1321.	1.4	2
10	Estimated Thresholds of Minimum Necessary Adherence for Effective Treatment with Direct Oral Anticoagulants – A Retrospective Cohort Study in Health Insurance Claims Data. Patient Preference and Adherence, 2021, Volume 15, 2209-2220.	0.8	4
11	The impact of a computerized physician order entry system implementation on 20 different criteria of medication documentation—a before-and-after study. BMC Medical Informatics and Decision Making, 2021, 21, 279.	1.5	6
12	Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants. Medical Decision Making, 2021, , 0272989X2110646.	1.2	6
13	Teaching reproducible research for medical students and postgraduate pharmaceutical scientists. BMC Research Notes, 2021, 14, 445.	0.6	0
14	Using the Causal Inference Framework to Support Individualized Drug Treatment Decisions Based on Observational Healthcare Data. Clinical Epidemiology, 2020, Volume 12, 1223-1234.	1.5	5
15	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. Journal of Pharmaceutical Sciences, 2020, 109, 2090-2094.	1.6	6
16	Pain severity and analgesics use in the community-dwelling older population: a drug utilization study from Germany. European Journal of Clinical Pharmacology, 2020, 76, 1695-1707.	0.8	3
17	Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity. Journal of Pharmacokinetics and Pharmacodynamics, 2020, 47, 527-542.	0.8	1
18	Osteoporotic hip fracture prediction from risk factors available in administrative claims data – A machine learning approach. PLoS ONE, 2020, 15, e0232969.	1.1	25

ANDREAS D MEID

#	Article	IF	CITATIONS
19	A framework to build similarity-based cohorts for personalized treatment advice – a standardized, but flexible workflow with the R package SimBaCo. PLoS ONE, 2020, 15, e0233686.	1.1	5
20	Reporter cell assay-based functional quantification of TNF-α-antagonists in serum – a proof-of-principle study for adalimumab. Analytical Biochemistry, 2020, 596, 113646.	1.1	3
21	Are Anticholinergic Symptoms a Risk Factor for Falls in Older General Practice Patients With Polypharmacy? Study Protocol for the Development and Validation of a Prognostic Model. Frontiers in Pharmacology, 2020, 11, 577747.	1.6	4
22	Title is missing!. , 2020, 15, e0232969.		0
23	Title is missing!. , 2020, 15, e0232969.		0
24	Title is missing!. , 2020, 15, e0232969.		0
25	Title is missing!. , 2020, 15, e0232969.		0
26	The Role of Adherence Thresholds for Development and Performance Aspects of a Prediction Model for Direct Oral Anticoagulation Adherence. Frontiers in Pharmacology, 2019, 10, 113.	1.6	8
27	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	1.8	27
28	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. British Journal of Clinical Pharmacology, 2018, 84, 2903-2913.	1.1	17
29	Prediction of Drug-Related Risks Using Clinical Context Information in Longitudinal Claims Data. Value in Health, 2018, 21, 1390-1398.	0.1	8
30	Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice. BMC Family Practice, 2018, 19, 131.	2.9	30
31	The impact of potentially inappropriate medication on the development of health care costs and its moderation by the number of prescribed substances. Results of a retrospective matched cohort study. PLoS ONE, 2018, 13, e0198004.	1.1	20
32	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLC–MS/MS-Based Assay. Analytical Chemistry, 2018, 90, 9395-9402.	3.2	33
33	Pill-count and the arithmetic of risk: Evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of adverse drug events. International Journal of Clinical Pharmacology and Therapeutics, 2018, 56, 572-576.	0.3	8
34	How can we define and analyse drug exposure more precisely to improve the prediction of hospitalizations in longitudinal (claims) data?. European Journal of Clinical Pharmacology, 2017, 73, 373-380.	0.8	5
35	Health Service Use, Costs, and Adverse Events Associated with Potentially Inappropriate Medication in Old Age in Germany: Retrospective Matched Cohort Study. Drugs and Aging, 2017, 34, 289-301.	1.3	48
36	Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data. Drug Safety, 2017, 40, 133-144.	1.4	29

ANDREAS D MEID

#	Article	IF	CITATIONS
37	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 433-439.	1.1	7
38	Is Polypharmacy Associated with Frailty in Older People? Results From the <scp>ESTHER</scp> Cohort Study. Journal of the American Geriatrics Society, 2017, 65, e27-e32.	1.3	154
39	Association of preventable adverse drug events with inpatients' length of stay-A propensity-matched cohort study. International Journal of Clinical Practice, 2017, 71, e12990.	0.8	19
40	Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Therapeutic Advances in Psychopharmacology, 2017, 7, 251-264.	1.2	43
41	Refining estimates of prescription durations by using observed covariates in pharmacoepidemiologic databases: Necessary refinements to stimulate alternative approaches. Pharmacoepidemiology and Drug Safety, 2017, 26, 1135-1137.	0.9	2
42	Realâ€world complexity of atrial fibrillation treatment with oral anticoagulants: design and interpretation of pharmacoepidemiological studies. British Journal of Clinical Pharmacology, 2017, 83, 2321-2324.	1.1	1
43	Comparative evaluation of methods approximating drug prescription durations in claims data: modeling, simulation, and application to real data. Pharmacoepidemiology and Drug Safety, 2016, 25, 1434-1442.	0.9	14
44	<i>SLCO1B1</i> Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine. OMICS A Journal of Integrative Biology, 2016, 20, 538-545.	1.0	22
45	Age-Dependent Impact of Medication Underuse and Strategies for Improvement. Gerontology, 2016, 62, 491-499.	1.4	6
46	Longitudinal evaluation of medication underuse in older outpatients and its association with quality of life. European Journal of Clinical Pharmacology, 2016, 72, 877-885.	0.8	19
47	Impact of an electronic clinical decision support system on workflow in antenatal care: the QUALMAT eCDSS in rural health care facilities in Ghana and Tanzania. Global Health Action, 2015, 8, 25756.	0.7	40
48	The impact of pharmaceutical care interventions for medication underuse in older people: a systematic review and metaâ€analysis. British Journal of Clinical Pharmacology, 2015, 80, 768-776.	1.1	38
49	Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study. PLoS ONE, 2015, 10, e0136339.	1.1	31
50	Role of NR1I2 (pregnane X receptor) polymorphisms in head and neck squamous cell carcinoma. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1141-1150.	1.4	12